First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Shaily Engineering Plastics: the setup is constructive — New contract wins with global pharmaceutical/medical device OEMs (multi-year programs worth $10-50M annually)
growth - 62% net income growth, 22% revenue growth, and 28.5% ROE attract growth investors seeking exposure to India's pharmaceutical…
moderate - Rising US rates impact valuation multiples for high-growth healthcare stocks (current 36x EV/EBITDA compresses with higher…
Watch on earnings: Global pharmaceutical R&D spending and new drug/device approval rates (proxy for future contract pipeline), Indian rupee/USD exchange rate (DEXINUS) - impacts export competitiveness and translated revenue, Crude oil prices (feedstock for engineering plastics and resins) - 6-9 month lag to margin impact.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $13.0B to $16.6B as new contract wins with global pharmaceutical/medical device oems (multi-year programs worth $10-50m annually).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.